Against bladder sparing: Surgery

被引:46
作者
Montie, JE [1 ]
机构
[1] Univ Michigan, Urol Sect, Ann Arbor, MI 48109 USA
关键词
bladder; neoplasm invasiveness; cystectomy;
D O I
10.1016/S0022-5347(05)68584-9
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: The efficacy of bladder preservation strategies for invasive cancer of the bladder are evaluated. Materials and Methods: The literature was reviewed specifically regarding the relative success of bladder preservation therapy compared with total cystectomy. Results: Bladder preservation strategies currently available are substantially inferior to cystectomy for elimination of the existing cancer and prevention of pelvic recurrence (soft tissue after cystectomy or in the bladder after bladder preservation). The best bladder preservation protocols eliminate cancer from the bladder at first evaluation in 10 to 20% and 50 to 80% of patients with T3b and T2 cancers, respectively, while later recurrences in the bladder are seen in 40 to 60%. Cystectomy provides a local failure rate of 10 to 25% for T2 and T3b disease, respectively. In addition, bladder reconstruction with a neobladder after cystectomy minimizes deterioration of quality of life which is the motivating rationale for bladder preservation. Conclusions: While continuing clinical trials of new strategies for bladder preservation are necessary and laudable, clinical practice currently affirms cystectomy, possibly with neobladder formation, as optimal therapy in appropriate patients.
引用
收藏
页码:452 / 455
页数:4
相关论文
共 51 条
  • [1] Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: Multivariate analysis on prognostic factors
    Angulo, JC
    SanchezChapado, M
    Lopez, JI
    Flores, N
    [J]. JOURNAL OF UROLOGY, 1996, 155 (06) : 1897 - 1902
  • [2] ABSENCE OF IMMUNOHISTOCHEMICAL METALLOTHIONEIN STAINING IN BLADDER-TUMOR SPECIMENS PREDICTS RESPONSE TO NEOADJUVANT CISPLATIN, METHOTREXATE AND VINBLASTINE CHEMOTHERAPY
    BAHNSON, RR
    BECICH, M
    ERNSTOFF, MS
    SANDLOW, J
    COHEN, MB
    WILLIAMS, RD
    [J]. JOURNAL OF UROLOGY, 1994, 152 (06) : 2272 - 2275
  • [3] Concurrent cisplatin and radiotherapy for patients with muscle invasive bladder cancer who are not candidates for radical cystectomy
    Chauvet, B
    Brewer, Y
    FelixFaure, C
    Davin, JL
    Choquenet, C
    Reboul, F
    [J]. JOURNAL OF UROLOGY, 1996, 156 (04) : 1258 - 1262
  • [4] The treated natural history of high risk superficial bladder cancer: 15-year outcome
    Cookson, MS
    Herr, HW
    Zhang, ZF
    Soloway, S
    Sogani, PC
    Fair, WR
    [J]. JOURNAL OF UROLOGY, 1997, 158 (01) : 62 - 67
  • [5] Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or definitive radiation
    Coppin, CML
    Gospodarowicz, MK
    James, K
    Tannock, IF
    Zee, B
    Carson, J
    Pater, J
    Sullivan, LD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (11) : 2901 - 2907
  • [6] EAPEN L, 1995, P AN M AM SOC CLIN, V14, pA625
  • [7] Combination transurethral resection, systemic chemotherapy, and pelvic radiotherapy for invasive (T2-T4) bladder cancer unsuitable for cystectomy: A Phase I/II Southwestern Oncology Group study
    Einstein, AB
    Wolf, M
    Halliday, KR
    Miller, GJ
    Hafermann, M
    Lowe, BA
    Meyers, FJ
    Leimert, JT
    Crawford, ED
    [J]. UROLOGY, 1996, 47 (05) : 652 - 657
  • [8] BLADDER-SPARING MULTIMODALITY TREATMENT OF MUSCLE-INVASIVE BLADDER-CANCER - A 5-YEAR FOLLOW-UP
    GIVEN, RW
    PARSONS, JT
    MCCARLEY, D
    WAJSMAN, Z
    [J]. UROLOGY, 1995, 46 (04) : 499 - 504
  • [9] Gospodarowicz M K, 1993, Semin Urol, V11, P214
  • [10] METACHRONOUS MULTIFOCAL DEVELOPMENT OF UROTHELIAL CANCERS BY INTRALUMINAL SEEDING
    HABUCHI, T
    TAKAHASHI, R
    YAMADA, H
    KAKEHI, Y
    SUGIYAMA, T
    YOSHIDA, O
    [J]. LANCET, 1993, 342 (8879) : 1087 - 1088